aTyr Pharma, Inc.(US:ATYR) Globenewswireยท2025-10-10 23:24Core Points - A class action has been filed on behalf of investors who purchased aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025 [1] - The allegations involve misleading statements regarding the efficacy of aTyr's drug candidate, Efzofitimod, during a Phase 3 clinical trial for pulmonary sarcoidosis [2] - Following the announcement that the EFZO-FIT study did not meet its primary endpoint, aTyr's stock price plummeted by 83.2%, from $6.03 to $1.02 per share in one day [3] Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing therapies for fibrosis and inflammation through evolutionary intelligence [1] Legal Proceedings - Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by December 8, 2025 [4] - The representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]